NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Enrolling By InvitationPhase 4

Sponsor: Mayo Clinic

Conditions: Obesity, Menopause

Interventions: semaglutide or tirzepatide, Lifestyle modification intervention

Countries: United States

In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.

Eligibility overview

Sex: FEMALE

Age: 46 Years to 60 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months or history of bilateral oophorecomy)
* Age 46-60 years old
* BMI ≥ 30 kg/m2.

Exclusion Criteria:

* Past or current use of menopausal hormone therapy
* Early or premature menopause
* History of chemically induced menopause
* Impaired renal function (GFR ≤29)
* Thyroid-stimulating hormone ≥7 with low free T4
* Diabetes
* Cardiovascular disease
* Elevated blood pressure (\>170/\>95)
* Uncontrolled co-morbidities including inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, or psychiatric disease
* \>5% change in weight during the 3 months prior to screening
* Other anti-obesity medication use within the past 3 months
* History of bariatric surgery
* History of malignant neoplasms within the past 5 years prior to screening
* Current use of supplements known to affect weight
* Personal or family history of medullary thyroid cancer.
* Wheelchair bound
* Vision loss

Locations (1)

Jacksonville, Florida, United States